Mineral Chemistry of Olivine, Oxy-Spinel, and Clinopyroxene in Lavas and Xenoliths from the Canary, Azores, and Cape Verde Islands (Macaronesia, North Atlantic Ocean): New Data and Comparisons with the Literature

An electron microprobe study was carried out on olivine, clinopyroxene, and oxy-spinel occurring in basalts and dunite xenoliths from the archipelagos of the Azores, the Canary Islands, and Cape Verde. By comparing our results with previously published data from the volcanic islands of Macaronesia, we confirmed the validity of the compositions of olivine, clinopyroxene, and oxy-spinel as geochemical tracers. The origin of olivine, i.e., crystallized in the lithospheric mantle or in volcanic rocks, was successfully discriminated. Olivine from Lanzarote dunite xenoliths, which represent fragments of the mantle transported to the surface by host magmas, exhibited higher Fo% values (Fo91.02 to Fo91.94) and a different distribution of minor elements Ca, Ni, and Mn (CaO up to 0.42 wt%, NiO 0.07–0.41 wt%, MnO 0.06–0.3 wt%) when compared with olivine occurring as phenocrysts in basaltic lavas from the Macaronesian islands. The highly variable forsterite contents (Fo75.1 to Fo94.4) in olivine from gabbro and peridotite xenoliths found across the islands of Macaronesia were attributed to fractional crystallization that started in a deep magma reservoir, suggesting that these xenoliths represent cumulate rocks and not mantle fragments. Alternatively, these xenoliths may have been affected by the interaction with metasomatic fluids. The composition of clinopyroxene phenocrysts was used to decipher formation conditions under extensional tectonics. Their composition suggests that the host lavas have an alkaline to calc-alkaline signature. Furthermore, clinopyroxene euhedral shapes and compositions suggest an origin by fractional crystallization in a closed magmatic system. The composition alone of oxy-spinel from Macaronesian basalts and xenoliths was not sufficient to draw conclusions about the geodynamic environment where they were formed. Nevertheless, the relationship between oxy-spinel and olivine crystallized in equilibrium was successfully used as oxybarometers and geothermometers. The oxy-spinel–olivine pairs show evidence that the basaltic lavas were crystallized from melts with higher oxygen fugacity and different cooling histories than those of the mantle xenoliths, as the latter crystallized and re-equilibrated much slower than the basalts

Convalescent Plasma for Hospitalized COVID-19 Patients: A Single-Center Experience

In Winter 2020, Italy, and in particular the Lombardy region, was the first country in the Western hemisphere to be hit by the COVID-19 pandemic. Plasma from individuals recovered from COVID-19 (COVID-19 convalescent plasma, CCP) was the first therapeutic tool adopted to counteract the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In this retrospective cohort study, we report the experience of the city hospital of Mantua, Lombardy region, on the compassionate use of CCP in patients hospitalized for severe COVID-19. Between April 2020 and April 2021, 405 consecutive COVID-19 patients received 657 CCP units with a median anti-SARS-CoV-2 neutralizing antibody (nAb) titer of 160 (interquartile range (IQR), 80–320). Their median age was 68 years (IQR, 56–78 years), and 62% were males. At enrollment, 55% of patients had an increased body mass index (BMI), and 25.6% had at least three comorbidities. The 28-day crude mortality rate was 12.6% (51/405). Young age (<68 years), mild disease (admission to low-intensity departments) and early treatment (<7 days from symptoms onset) with high nAb titer (≥320) CCP were found as independently associated with a favorable response to CCP treatment. No safety concerns were recorded, with a rate of CCP-related adverse reactions (all of mild intensity) of 1.3%. In our real-life experience, the first in the western world, early administration of high-titer CCP was a safe and effective treatment for hospitalized COVID-19 patients

Abstracts from the 23rd Italian congress of Cystic Fibrosis and the 13th National congress of Cystic Fibrosis Italian Society

Cystic Fibrosis (CF) occurs most frequently in caucasian populations. Although less common, this disorder have been reported in all the ethnicities. Currently, there are more than 2000 described sequence variations in CFTR gene, uniformly distributed and including variants pathogenic and benign (CFTR1:www.genet.sickkids.on.ca/). To date,only a subset have been firmily established as variants annotated as disease-causing (CFTR2: www.cftr2.org). The spectrum and the frequency of individual CFTR variants, however, vary among specific ethnic groups and geographic areas. Genetic screening for CF with standard panels of CFTR mutations is widely used for the diagnosis of CF in newborns and symptomatic patients, and to diagnose CF carrier status. These screening panels have an high diagnostic sensitivity (around 85%) for CFTR mutations in caucasians populations but very low for non caucasians. Developed in the last decade, Next-Generation Sequencing (NGS) has been the last breakthrough technology in genetic studies with a substantial reduction in cost per sequenced base and a considerable enhancement of the sequence generation capabilities. Extended CFTR gene sequencing in NGS includes all the coding regions, the splicing sites and their flankig intronic regions, deep intronic regions where are localized known mutations,the promoter and the 5'-3' UTR regions. NGS allows the analysis of many samples concurrently in a shorter period of time compared to Sanger method . Moreover, NGS platforms are able to identify CFTR copy number variation (CNVs), not detected by Sanger sequencing. This technology has provided new and reliable approaches to molecular diagnosis of CF and CFTR-Related Disorders. It also allows to improve the diagnostic sensitivity of newborn and carrier screeningmolecular tests. In fact, bioinformatics tools suitable for all the NGS platforms can filter data generated from the gene sequencing, and analyze only mutations with well-established disease liability. This approach allows the development of targeted mutations panels with a higher number of frequent CF mutations for the target populationcompared to the standard panels and a consequent enhancement of the diagnostic sensitivity. Moreover, in the emerging challenge of diagnosing CF in non caucasians patients, the possibility of customize a NGS targeted mutations panel should increase the diagnostic sensitivity when the target population has different ethnicities